Jynge P, Skjetne T, Gribbestad I, Kleinbloesem C H, Hoogkamer H F, Antonsen O, Krane J, Bakøy O E, Furuheim K M, Nilsen O G
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Norway.
Clin Pharmacol Ther. 1990 Nov;48(5):481-9. doi: 10.1038/clpt.1990.183.
Magnetic resonance spectroscopy of fluorine (19F) has been used to noninvasively study the in vivo pharmacokinetics of a model drug, fleroxacin (a fluoroquinolone antibiotic agent), in healthy human subjects. After oral administration, fleroxacin was detected in 19F magnetic resonance spectra from both liver and calf muscle and four magnetic resonance examinations were undertaken during a 24-hour period. By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma. The study documents for the first time the potential use of 19F magnetic resonance spectroscopy to noninvasively observe the time-related changes of a fluorine-containing drug in human tissues after oral administration.
氟(19F)磁共振波谱已被用于在健康人体受试者中无创研究模型药物氟罗沙星(一种氟喹诺酮类抗生素)的体内药代动力学。口服给药后,在肝脏和小腿肌肉的19F磁共振谱中检测到氟罗沙星,并在24小时内进行了四次磁共振检查。通过将高效液相色谱法的血浆分析与磁共振数据相结合,获得了以下药代动力学参数(平均值):肝脏、血浆和肌肉中的tmax分别为1.4、4.6和5.6小时;血浆、肝脏和肌肉中的Cmax分别为53、约250和约60μmol/L;肝脏中的t1/2为4.4小时(快相)和10.8小时(慢相),血浆中的t1/2为14.2小时。该研究首次证明了19F磁共振波谱在无创观察口服含氟药物在人体组织中随时间变化方面的潜在用途。